financetom
Business
financetom
/
Business
/
UniCredit to seek ECB approval to potentially buy up to 30% of Commerzbank, sources say
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
UniCredit to seek ECB approval to potentially buy up to 30% of Commerzbank, sources say
Sep 17, 2024 6:11 AM

MILAN (Reuters) - UniCredit will seek ECB clearance to potentially buy up to 30% of Commerzbank, three people close to the matter said, in order to have the "flexibility" the Italian bank's CEO Andrea Orcel said he needs to plan his next move.

UniCredit emerged as the biggest private investor in Commerzbank after it outbid rivals in a tender to buy a 4.5% stake from the German government. UniCredit had previously bought another 4.5% stake on the market.

The European Central Bank vets investors who want to own at least 10% of a bank, to ensure they are a suitable shareholder. The same applies for thresholds of 20%, 30% or 50%.

UniCredit's 9% holding in Commerzbank, which has been a takeover target for the Italian lender for more than two decades, could lead to a full takeover, Orcel has said, provided there is broad support for a deal that will "create added value for Commerzbank, UniCredit, Germany and Europe."

UniCredit could also just keep the current stake or sell it, Orcel has said. In disclosing the stake, UniCredit said it would seek ECB approval to potentially raise it above 9.9%, so that it could then move "if and when necessary".

UniCredit plans to seek approval to potentially acquire a stake of up to 30% because that is the threshold that under German rules triggers a mandatory buyout offer, the three people close to the matter told Reuters.

The filing is expected in the next few days, they added.

Il Messaggero daily first reported news of the up to 30% threshold.

UniCredit will apply to Germany's financial regulator BaFin, which will then send on the request to the ECB. The ECB has up to 60 days to reply, which can be extended to 90 if necessary.

Investors normally apply for successive thresholds, triggering a separate authorisation process every time.

By seeking clearance to increase the Commerzbank stake to just below the mandatory buyout offer threshold, UniCredit will secure the widest room for manoeuvre in the shortest timeframe.

"We want the flexibility, because as a private investor, at the moment, we may go up, we may go down, and we may combine," Orcel told Bloomberg television last week. "Unless we ask for the authorisation first, we don't have that flexibility."

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
MicroStrategy Opens $525 Million Offering of Convertible Senior Notes
MicroStrategy Opens $525 Million Offering of Convertible Senior Notes
Mar 15, 2024
08:52 AM EDT, 03/15/2024 (MT Newswires) -- MicroStrategy ( MSTR ) said Friday that it is offering 0.875% convertible senior notes due 2031 for an aggregate of $525 million. The notes will be unsecured, payable semi-annually in arrears on March 15 and Sept. 15 of each year and will mature on March 15, 2031. MicroStrategy ( MSTR ) said it...
Getty Images to Materially Outperform Expectations Despite Soft 2024 Guidance, Wedbush Says
Getty Images to Materially Outperform Expectations Despite Soft 2024 Guidance, Wedbush Says
Mar 15, 2024
08:54 AM EDT, 03/15/2024 (MT Newswires) -- Getty Images ( GETY ) could materially outperform Wedbush Securities' expectations amid potential economic improvement, even though the visual content creation company issued a lower-than-anticipated full-year outlook, the brokerage said in a client note Friday. The company late Thursday outlined revenue to be in a range of $928 million to $947 million for...
Arch Biopartners Says University of Calgary Joins Phase II Trial of LSALT Peptide Targeting Cardiac Surgery-Associated AKI
Arch Biopartners Says University of Calgary Joins Phase II Trial of LSALT Peptide Targeting Cardiac Surgery-Associated AKI
Mar 15, 2024
08:50 AM EDT, 03/15/2024 (MT Newswires) -- Arch Biopartners Inc. ( ACHFF ), (ARCH.V) announced Friday that a research team from the University of Calgary's Cumming School of Medicine has joined the Phase II trial for LSALT peptide targeting the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI). LSALT peptide is the company's lead drug candidate for preventing...
Groupon Swings to Q4 Non-GAAP Net Income, Revenue Falls; Says Going Concern Issue Resolved
Groupon Swings to Q4 Non-GAAP Net Income, Revenue Falls; Says Going Concern Issue Resolved
Mar 15, 2024
08:54 AM EDT, 03/15/2024 (MT Newswires) -- Groupon ( GRPN ) reported Q4 non-GAAP net income Friday of $0.30 per diluted share, swinging from a loss of $0.38 a year earlier. Two analysts polled by Capital IQ expected $0.12. Revenue for the quarter ended Dec. 31 was $137.7 million, down from $148.2 million last year. Two analysts surveyed by Capital...
Copyright 2023-2026 - www.financetom.com All Rights Reserved